Christoph Huber | |
|---|---|
 | |
| Born | |
| Occupation | Cardiac Surgeon; Medical device inventor; Author |
Christoph Huber MD, FMH, FECTS is a Swiss cardiac surgeon who is a professor and the head of the Division of Cardiac and Vascular Surgery at the University Hospital Geneva, Switzerland. [1] [2]
Huber also maintains a research program, [3] is an inventor, book author and entrepreneur, having founded the company Endoheart AG. [4] He is the inventory of the transapical (TA) TAVI for cardiac surgery
Christoph Huber completed his Dr. med. at the Bern University Medical School in Basel, Switzerland, his General Surgery Residency at the District Hospital Biel in Biel and his Cardiovascular Residency at the University Hospital Bern, Inselspital, Switzerland. [1]
Between 2002-07/08, Huber attended the University Hospital Lausanne (including a senior cardiac surgical clinical fellowship 2004–05 at Brigham and Women's Hospital, Harvard Medical School, Boston, USA) and Great Ormond Street Hospital, London, UK (Senior Fellow Congential Cardiac Surgery); returning to University Hospital Bern in 2009 as a Senior Consultant Cardiovascular Surgeon (MD, FMH), Director of the Surgical Transcatheter Valve Implantation (TAVI) Program, lecturer, and Medical Superintendent of adult cardiac surgery. [1] [5]
In 2016, Huber became the Head of Division Cardiac and Vascular Surgery (Médecin-chef de service) at the University Hospital Geneva (HUG). [1] [2] Huber also published a textbook on transcatheter valve therapies (TCVT) in 2009. [5]
Huber developed the transapical (TA) TAVI [5] in 2004 which introduced a less invasive antegrade, versus transfemoral/TF retrograde, approach to the heart, [6] [7] [8] [9] and his later research, into a percutaneous transapical TAVI platform, led to his invention of the first successful experimental closure device (TA Plug). [7] [8] [10] Huber also opened a startup company [4] and assisted in the development of the Acurate TA (Symetis) device which received CE approval in 2011. [11] [12] [13]
Interventional cardiology is a branch of cardiology that deals specifically with the catheter based treatment of structural heart diseases. Andreas Gruentzig is considered the father of interventional cardiology after the development of angioplasty by interventional radiologist Charles Dotter.
Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve. The aortic valve may need to be replaced because:
Valve replacement surgery is the replacement of one or more of the heart valves with either an artificial heart valve or a bioprosthesis. It is an alternative to valve repair.
Percutaneous aortic valve replacement (PAVR), also known as percutaneous aortic valve implantation (PAVI), transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR), is the replacement of the aortic valve of the heart through the blood vessels. The replacement valve is delivered via one of several access methods: transfemoral, transapical, subclavian, direct aortic, and transcaval, among others.
Mitral valve replacement is a procedure whereby the diseased mitral valve of a patient's heart is replaced by either a mechanical or tissue (bioprosthetic) valve.
David H. Adams is an American cardiac surgeon and the Marie-Josée and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai Hospital in New York City. Dr. Adams is a recognized leader in the field of heart valve surgery and mitral valve reconstruction. As director of Mount Sinai Mitral Valve Repair Center, he has set national benchmarks with >99% degenerative mitral valve repair rates, while running one of the largest valve repair programs in the United States. Dr. Adams is the co-inventor of 2 mitral valve annuloplasty repair rings – the Carpentier-McCarthy-Adams IMR ETlogix Ring and the Carpentier-Edwards Physio II Annuloplasty Ring, and is a senior consultant with royalty agreements with Edwards Lifesciences. He is also the inventor of the Tri-Ad Adams Tricuspid Annuloplasty ring with a royalty agreement with Medtronic. He is a co-author with Professor Alain Carpentier of the benchmark textbook in mitral valve surgery Carpentier's Reconstructive Valve Surgery. He is also the National Co-Principal Investigator of the FDA pivotal trial of the Medtronic-CoreValve transcatheter aortic valve replacement device.
Cardiothoracic anesthesiology is a subspeciality of the medical practice of anesthesiology, devoted to the preoperative, intraoperative, and postoperative care of adult and pediatric patients undergoing cardiothoracic surgery and related invasive procedures.
Marian Ion Ionescu is a Romanian-born British cardiac surgeon. His interest in heart surgery covered several aspects of this specialty. He was an inventor of surgical devices, mostly artificial heart valves, a scientist in the broad term and a medical educator.
The pericardial heart valve was invented by Marian Ionescu, a British surgeon working at the General Infirmary in Leeds, England. He created this artificial bioprosthetic heart valve as a three-cusp structure made of chemically treated bovine pericardium attached to a Dacron cloth-covered titanium frame.
Lars Georg Svensson is a cardiac surgeon and the chairman of the heart and vascular institute at Cleveland Clinic. He is the Director of the Aorta Center, Director of the Marfan Syndrome and Connective Tissue Disorder Clinic, and is a professor of surgery at Cleveland Clinic Lerner College of Medicine and Case Western Reserve University. He is also the Director of Quality Outcomes and Process Improvement for the Department of Thoracic and Cardiovascular Surgery and Affiliate Cardiac Surgery Program at Cleveland Clinic.
A hybrid cardiac surgical procedure in a narrow sense is defined as a procedure that combines a conventional, more invasive surgical part with an interventional part, using some sort of catheter-based procedure guided by fluoroscopy imaging in a hybrid operating room (OR) without interruption. The hybrid technique has a reduced risk of surgical complications and has shown decreased recovery time. It can be used to treat numerous heart diseases and conditions and with the increasing complexity of each case, the hybrid surgical technique is becoming more common.
Gilles Dreyfus is a French cardiac surgeon.
The European Association for Cardio-Thoracic Surgery (EACTS) is a membership organisation devoted to the practice of cardiothoracic surgery. The mission statement of the association is to advance education in the field of cardiac, thoracic and vascular interventions; and promote research into cardiovascular and thoracic physiology, pathology and therapy, with the aim to correlate and disseminate the results for the public benefit. Within the EACTS there is a large number of committees working on various issues in order to improve cardio-thoracic surgery.
Giuseppe Di Bendetteo is an Italian cardiac surgeon born in Eboli on 8 January 1946, He holds the Italian national record for the use of carbon dioxide laser to perform revascularization trans-myocardial otherwise inoperable; specialized in congenital diseases of cardiovascular system, is one of the few surgeons in the world that practice successfully the surgery of aortic arch.
Alain Cribier, FACC, FESC is a French interventional cardiologist, who is a Professor of Medicine and Director of Cardiology at the University of Rouen's Charles Nicolle Hospital. Alain Cribier is best known for performing the world's first transcatheter aortic valve implantation in 2002, the first mitral commissurotomy in 1995 and the first balloon aortic valvuloplasty in 1986.
John G. Webb, M.D., FRCPC is a Canadian interventional cardiologist and the McLeod Professor of Heart Valve Intervention at the University of British Columbia. He is most well known for performing the first transfemoral and the first transapical transcatheter aortic valve implantation in the world both in 2005. He completed the first ever transcatheter mitral valve-in-valve replacement in 2009 and the first in-human TMVR to be completed with the Neovasc Tiara device in 2014. In addition, he was an investigator in the PARTNER trial, a randomized clinical trial demonstrating the efficacy of TAVI compared to aortic valve replacement and medical intervention.
Christian-Friedrich Vahl is a German cardiac surgeon. He is director of the Clinic for Heart, Thorax and Vascular surgery at the University of Mainz.
Michael J. Reardon is an American cardiac surgeon and medical researcher. He is known for his work in heart autotransplantation for malignant heart tumors, an operation in which the surgeon removes the patient's heart, cuts out the malignant tumor, and reimplants the heart back in the patient's chest. He performed the first successful heart autotransplantation for a cancerous heart tumor in 1998. Dr. Reardon has served as a leading clinical investigator in the trans catheter aortic valve replacement (TAVR) field. He serves as the national surgical principal investigator for the Evolut intermediate risk trial ,the Evolut low risk trial (NCT02701283), the Evvolut 34 mm trial (NCT02746809), the Evolut 2.0trial (NCT02738853), the Reprise III Lotus high and Extreme risk trial (NCT02202434), The Acurate trial (NCT03735667), The Portico NG trial (NCT04011722) and the Vantage trial (NCT04788888). He serves a national study chair for the Reprove IV trial (NCT03618095) and the Evolut low risk bicuspid trial (NCT03635424).
Marjan Jahangiri FRCS, FRCS (CTh) is Professor of Cardiac Surgery at St. George's Hospital, University of London. She was the first woman to be appointed professor of cardiac surgery in the United Kingdom and Europe.
Percutaneous pulmonary valve implantation (PPVI), also known as transcatheter pulmonary valve replacement (TPVR), is the replacement of the pulmonary valve via catheterization through a vein. It is a significantly less invasive procedure in comparison to open heart surgery and is commonly used to treat conditions such as pulmonary atresia.